Industry Breathes Sigh Of Relief Over UK Batch Release Move
Executive Summary
One of the key regulatory conundrums thrown up by Brexit has been addressed after the government decided to continue using a list of approved countries to waive drug import testing requirements.
You may also be interested in...
Batch Testing ‘Could Double’ Under Govt Proposals For Great Britain
The UK government is consulting on a set of options for batch testing of imported medicines as it seeks to balance patient safety principles with the need to avoid overly burdensome import requirements.
EU Fees Revision A ‘Once-In-A-Generation’ Chance To Solve Resource Challenges
COVID-19 and Brexit have put a great strain on the resources of the EU medicines regulatory system, but the planned review of the EU fee system could produce a system that is more flexible, efficient and better able to respond rapidly to emerging technologies and the needs of health care systems, says EFPIA.
New French Body To Lead Efforts Against Drug Shortages
A new committee including representatives of the French pharma industry, health professionals and patients is to lay the groundwork for a longer-term approach to preventing and managing medicine supply chain issues. A separate initiative launched by the prime minister will look at medicines access issues and strengthening the French manufacturing base.